Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy simil...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Haematologica
Prif Awduron: San-Miguel, Jesus, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Farnsworth, Andrew, Nahi, Hareth, Chari, Ajai
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Fondazione Ferrata Storti 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168515/
https://ncbi.nlm.nih.gov/pubmed/32354874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243790
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg